EA
FLGT icon

Ellsworth Advisors’s Fulgent Genetics FLGT Stock Holding History

Ellsworth Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,016
Closed -$871K – 154
2021
Q1 		$871K Buy
9,016
+424
+5% +$43.8K 0.52% 61
2020
Q4 		$448K Buy
8,592
+1,339
+18% +$56K 0.32% 70
2020
Q3 		$290K Buy
+7,253
New +$227K 0.29% 66

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ellsworth Advisors's FLGT Position: Q2 2021 in Review

Ellsworth Advisors sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 9,016 shares — an estimated $871K sold.

Ellsworth Advisors first reported a position in FLGT in Q3 2020 and held it in 3 quarters. The position peaked at $871K in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

  • Ellsworth Advisors reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
  • Ellsworth Advisors sold 9,016 Fulgent Genetics shares in Q2 2021, an estimated $871K.
  • Ellsworth Advisors first reported a position in Fulgent Genetics in Q3 2020 and held it in 3 quarters.
  • Ellsworth Advisors's Fulgent Genetics position peaked at $871K in Q1 2021.
  • 254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Ellsworth Advisors's 13F filing for Q2 2021, filed 19 Jul 2021.